NRAS and myeloproliferative neoplasm: One of these patients had a diagnosis of MPN‐NOS with an NRAS G12D mutation and experienced an increase in white blood cell (WBC) from 54 × 109/L to 92 × 109/L with 3.5% blasts within a week of starting regorafenib, which resolved after stopping the treatment.